Binds Expression Product Of Cancer-related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 530/387.7)
-
Patent number: 7700742Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: June 2, 2005Date of Patent: April 20, 2010Assignees: Amgen Fremont, Pfizer, Inc.Inventors: Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo
-
Publication number: 20100093003Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: ApplicationFiled: December 11, 2009Publication date: April 15, 2010Inventor: Craig Jordan
-
Patent number: 7696326Abstract: The invention of the present application relates to a method for obtaining antibodies directed against a carbohydrate moiety contained in a carbohydrate peptide conjugate, by administering to a subject a composition containing a carbohydrate peptide conjugate and collecting the antibodies directed against the said carbohydrate moiety from a serum previously obtained from the subject.Type: GrantFiled: January 3, 2007Date of Patent: April 13, 2010Assignee: Institut PasteurInventors: Sylvie Bay, Daniele Cantacuzene, Claude Leclerc, Richard Lo-Man
-
Patent number: 7696325Abstract: This invention relates to reconstructed polypeptides which have properties of inducing apoptosis of nucleated blood cells having Integrin Associated Protein (IAP) and causing no hemagglutination. The reconstructed polypeptides comprise two or more H chain V regions and two or more L chain V regions of a monoclonal antibody which induces apoptosis of nucleated blood cells having IAP. The reconstructed polypeptides are useful as a therapeutic agent for blood dyscrasia such as leukemia.Type: GrantFiled: March 12, 2001Date of Patent: April 13, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Naoshi Fukushima, Masayuki Tsuchiya, Masayoshi Oh-Eda, Shinsuke Uno, Yasufumi Kikuchi
-
Patent number: 7691586Abstract: A method for prognosing possible recurrence after treatment of the liver cancer, characterized by measuring GPC3 contained in a test sample by use of an anti-GPC3 antibody.Type: GrantFiled: April 28, 2005Date of Patent: April 6, 2010Assignee: Perseus Proteomics Inc.Inventors: Kiyotaka Watanabe, Shin Ohnishi, Hiroyuki Aburatani, Yutaka Midorikawa, Yoshitaka Hippo, Hiroko Iwanari, Susumu Tokita, Hirokazu Satoh
-
Patent number: 7691376Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.Type: GrantFiled: May 24, 2007Date of Patent: April 6, 2010Assignee: ImmunoCellular Therapeutics, Ltd.Inventor: Cohava Gelber
-
Patent number: 7691978Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: September 27, 2006Date of Patent: April 6, 2010Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
-
Patent number: 7687606Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: December 19, 2006Date of Patent: March 30, 2010Assignee: AstraZeneca ABInventors: Jean M. Gudas, Mary Haak-Frendscho, Orit Foord, Meina L. Liang, Kiran Ahluwalia, Sunil Bhakta
-
Patent number: 7687464Abstract: This invention relates to methods for activation of T cell protein tyrosine phosphatase (TCPTP) and for inhibiting tyrosine kinase signalling in an individual. The invention concerns a method for preventing or treating a disease or disorder in an individual, wherein said disease or disorder is curable by inhibiting tyrosine kinase signalling, and a method for preventing cancer, or preventing or inhibiting cancer growth, invasion or metastasis in an individual, based on activating T cell protein tyrosine phosphatase (TCPTP). The invention also concerns pharmaceutical compositions useful in the methods.Type: GrantFiled: November 20, 2006Date of Patent: March 30, 2010Assignee: Valtion Teknillinen TutkimuskeskusInventors: Johanna Ivaska, Elina Mattila
-
Patent number: 7682612Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: November 9, 1999Date of Patent: March 23, 2010Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-López, John G. Curd, Susan Desmond-Hellmann
-
Patent number: 7674605Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: June 7, 2007Date of Patent: March 9, 2010Assignee: BioAlliance C.V.Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
-
Patent number: 7674883Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: GrantFiled: September 13, 2007Date of Patent: March 9, 2010Assignee: Facet Biotech CorporationInventors: Vinay Bhaskar, Agustin de la Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
-
Publication number: 20100056761Abstract: The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor.Type: ApplicationFiled: April 17, 2009Publication date: March 4, 2010Applicants: MERRIMACK PHARMACEUTICALS, INC., DYAX CORPInventors: Birgit SCHOEBERL, Ulrik NIELSEN, Michael FELDHAUS, Arumugam Muruganandam, David Buckler
-
Patent number: 7670600Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: April 3, 2006Date of Patent: March 2, 2010Assignees: MedImmine, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 7666425Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: July 20, 1999Date of Patent: February 23, 2010Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 7662383Abstract: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.Type: GrantFiled: February 7, 2008Date of Patent: February 16, 2010Assignee: Aventis Pharma Deutschland GmbHInventors: Klaus Bosslet, Gerhard Seemann, Hans Harald Sedlacek, Bernhard Auerbach
-
Patent number: 7659374Abstract: The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., Fc?R, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.Type: GrantFiled: August 15, 2005Date of Patent: February 9, 2010Assignee: MedImmune, LLCInventors: Herren Wu, Changshou Gao
-
Patent number: 7658924Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: November 4, 2004Date of Patent: February 9, 2010Assignee: Amgen Inc.Inventors: Jonathan Oliner, Kevin Graham
-
Publication number: 20100028347Abstract: Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti -VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.Type: ApplicationFiled: November 18, 2005Publication date: February 4, 2010Inventors: Yan Wu, Daniel J. Hicklin, Peter Bohlen
-
Patent number: 7655471Abstract: Endometrium secreted polypeptides are assayed in body fluids to determine the presence of polypeptides of specified pI and MW values that have been found to be regulated in body fluids according to the status of the endometrium, or the presence of hyperplasia or adenocarcinoma.Type: GrantFiled: January 17, 2003Date of Patent: February 2, 2010Assignee: Drugmode APSInventors: Inger Byrjalsen, Peter M. Larsen, Stephen J. Fey
-
Patent number: 7655234Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.Type: GrantFiled: April 1, 2005Date of Patent: February 2, 2010Assignee: Agensys, Inc.Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Aya Jakobovits
-
Publication number: 20100015641Abstract: The present invention provides a diagnostic agent and a diagnostic kit for tumor such as lung cancer, cervical cancer, gastric cancer, breast cancer or the like, which comprise an antibody against MCAF1 or MCAF2; and a diagnostic method using an antibody against MCAF1 or MCAF2.Type: ApplicationFiled: April 27, 2006Publication date: January 21, 2010Inventors: Mitsuyoshi Nakao, Takaya Ichimura, Takaaki Ito
-
Publication number: 20100015045Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: July 16, 2009Publication date: January 21, 2010Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp, Fortunata McConkey
-
Patent number: 7641891Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: October 30, 2007Date of Patent: January 5, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Patent number: 7638286Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: October 2, 2006Date of Patent: December 29, 2009Assignee: ZymoGenetics, Inc.Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
-
Patent number: 7638327Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: June 23, 2006Date of Patent: December 29, 2009Assignee: Biogen IDEC MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Patent number: 7635475Abstract: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen.Type: GrantFiled: August 18, 2003Date of Patent: December 22, 2009Assignee: Tohoku Techno Arch Co., Ltd.Inventors: Izumi Kumagai, Toshio Kudo, Kouhei Tsumoto, Ryutaro Asano
-
Patent number: 7635759Abstract: A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab) or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.Type: GrantFiled: February 11, 2008Date of Patent: December 22, 2009Assignee: Immvarx, Inc.Inventor: James A. Radosevich
-
Patent number: 7632924Abstract: Novel antigen-binding polypeptides (ABP) and uses thereof are provided.Type: GrantFiled: June 17, 2005Date of Patent: December 15, 2009Assignee: Ambrx, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Troy E. Wilson, Thomas P. Cujec, Feng Tian, Anna-Maria Hays, Bruce E. Kimmel, Lillian Ho
-
Publication number: 20090306347Abstract: Disclosed is an antibody produced using an ostrich. Also disclosed is a method for producing the antibody. By using an ostrich, it becomes possible to produce antibodies (particularly antibodies for medical use), which have been hardly produced by using the mammals such as the mouse and the rat, homogeneously in a single body, in large quantities and in a simple manner. The method can overcome a disadvantage of lot-to-lot variation which may occur in the production of polyclonal antibodies using other animals.Type: ApplicationFiled: August 29, 2006Publication date: December 10, 2009Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATIONInventor: Yasuhiro Tsukamoto
-
Publication number: 20090298195Abstract: Method for engineering an immunoglobulin comprising at least one modification in a structural loop region of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of:—providing a nucleic acid encoding an immunoglobulin comprising at least one structural loop region,—modifying at least one nucleotide residue of at least one of said structural loop regions,—transferring said modified nucleic acid in an expression system,—expressing said modified immunoglobulin,—contacting the expressed modified immunoglobulin with an epitope, and—determining whether said modified immunoglobulin binds to said epitope, as well as modified immunoglobulins.Type: ApplicationFiled: January 5, 2006Publication date: December 3, 2009Inventors: Florian Rüker, Gordana Wozniak-Knopp
-
Publication number: 20090298766Abstract: The present invention relates to methods and compositions for the detection and treatment of melanoma and skin cancers. More particularly, the invention discloses that BCSC-1 expression is altered in melanoma and skin cancer cells, allowing the design of effective detection methods and kits for such conditions. The invention also shows that restoring or increasing expression of BCSC-1 in melanoma and skin cancer cells suppresses tumorigenicity and represents a novel and effective approach for the treatment of melanoma and skin cancers. The invention may be used to detect the presence, stage or type of melanoma and skin cancers, as well as any predisposition thereto. The invention may be used in any mammalian subject, particularly human subjects.Type: ApplicationFiled: March 15, 2007Publication date: December 3, 2009Inventors: Vincent A. Piguet, Rafael Correa Rocha, Laurent Bracco
-
Patent number: 7622560Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.Type: GrantFiled: December 20, 2005Date of Patent: November 24, 2009Assignee: Dinona Inc.Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
-
Publication number: 20090286246Abstract: Provided herein are methods for screening compounds for their ability to modulate the expression of certain isoforms of proteins that are associated with cancer, such as isoforms of proteins that participate in Wnt signaling in cancer cells.Type: ApplicationFiled: May 7, 2009Publication date: November 19, 2009Applicant: WINTHERIX LLCInventors: John Hood, Charlene F. Barroga, Dennis Carson, Desheng Lu
-
Patent number: 7611708Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: October 6, 2008Date of Patent: November 3, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 7608696Abstract: This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of identifying and manufacturing therapeutic compounds, and methods of treating patients with invasive and metastatic breast cancer or degenerative neural conditions.Type: GrantFiled: April 23, 2004Date of Patent: October 27, 2009Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Kornelia Polyak, Dale Porter
-
Patent number: 7604947Abstract: The invention relates to method for detecting and modulating the expression and activity of REX-1. As described herein, REX-1 is expressed in certain cancer cells, including cancer stem cells. The invention also provides methods for detecting and/or treating cancer.Type: GrantFiled: June 8, 2005Date of Patent: October 20, 2009Assignee: Cornell Research Foundation, Inc.Inventor: Lorraine J. Gudas
-
Publication number: 20090258020Abstract: The invention provides antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of proliferating cells, such as hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder.Type: ApplicationFiled: January 6, 2009Publication date: October 15, 2009Applicant: PATRYS LIMITEDInventors: Heinz Peter Vollmers, Stephanie Ute Brandlein, Frank Hensel
-
Patent number: 7598052Abstract: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.Type: GrantFiled: October 10, 2006Date of Patent: October 6, 2009Assignee: The Regents of the University of MichiganInventors: Thomas Giordano, Ronald Koenig, Rork Kuick, Samir Hanish, Yuri Nikiforov, Dafydd G. Thomas
-
Patent number: 7598353Abstract: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.Type: GrantFiled: July 30, 2008Date of Patent: October 6, 2009Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, John McWhirter, Anke Kretz-Rommel, Toshiaki Maruyama
-
Patent number: 7595047Abstract: Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies.Type: GrantFiled: April 13, 2006Date of Patent: September 29, 2009Assignees: Duke University, Northwestern UniversityInventors: Tammy L. Moser, Salvatore V. Pizzo, Mary S. Stack
-
Publication number: 20090238830Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.Type: ApplicationFiled: February 27, 2009Publication date: September 24, 2009Inventor: Christian Rohlff
-
Patent number: 7592426Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.Type: GrantFiled: March 9, 2006Date of Patent: September 22, 2009Assignee: Morphotek, Inc.Inventors: Wolfgang Ebel, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass, Eric Routhier
-
Patent number: 7589180Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: GrantFiled: May 13, 2002Date of Patent: September 15, 2009Assignee: Abbott Laboratories Inc.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20090226442Abstract: The invention relates to antibodies which bind to RON (receptor d'origine nantais, MST1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific antibodies which inhibit RON-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific antibodies which block the ability of the ligand, MSP to bind to RON, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.Type: ApplicationFiled: January 22, 2009Publication date: September 10, 2009Inventors: Heather Huet, Veronique Bailly, Ellen Garber, Christilyn Graff, Steven Miklasz
-
Publication number: 20090226942Abstract: Disclosed herein are lung cancer specific binding agents, as well as related amino acid and nucleic acid sequences. Methods of using such agents in the diagnosis and treatment of treat lung cancer are also disclosed. In an embodiment of the invention there is provided an antibody or fragment thereof comprising the sequence Ser Gly Asn Gly Gly Thr in the region corresponding to the CDR 2.Type: ApplicationFiled: March 27, 2008Publication date: September 10, 2009Inventors: Colin Roger MacKenzie, Qinggang Li, Jianbing Zhang
-
Patent number: 7585505Abstract: A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.Type: GrantFiled: April 1, 2005Date of Patent: September 8, 2009Assignee: Agensys, Inc.Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Aya Jakobovits
-
Publication number: 20090220510Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 23, 2008Publication date: September 3, 2009Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gred Ritter, Achim Jungbluth, Elisabeth Stockert, V. Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20090220991Abstract: The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.Type: ApplicationFiled: February 29, 2008Publication date: September 3, 2009Inventors: Roberto Polakiewicz, Valerie Goss, Albrecht Moritz, Ting-Lei Gu, Kimberly Lee
-
Patent number: RE40948Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.Type: GrantFiled: October 24, 2001Date of Patent: October 27, 2009Assignees: The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of UtahInventors: Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White